Evaluation of inflammation‑based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy

Asama,Hiroyuki; Suzuki,Rei; Takagi,Tadayuki; Sugimoto,Mitsuru; Konno,Naoki; Watanabe,Ko; Nakamura,Jun; Kikuchi,Hitomi; Takasumi,Mika; Sato,Yuki; Irie,Hiroki; Hikichi,Takuto; Ohira,Hiromasa

doi:10.3892/mco.2018.1696

Evaluation of inflammation‑based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy

Authors:
- Hiroyuki Asama
- Rei Suzuki
- Tadayuki Takagi
- Mitsuru Sugimoto
- Naoki Konno
- Ko Watanabe
- Jun Nakamura
- Hitomi Kikuchi
- Mika Takasumi
- Yuki Sato
- Hiroki Irie
- Takuto Hikichi
- Hiromasa Ohira
View Affiliations

Affiliations: Department of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima 960‑1247, Japan, Department of Endoscopy, Fukushima Medical University, School of Medicine, Fukushima 960‑1247, Japan
Published online on: August 10, 2018 https://doi.org/10.3892/mco.2018.1696
Pages: 408-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Predicting the prognosis of unresectable pancreatic ductal adenocarcinoma (PDAC) is useful in determining the appropriate management strategy. The present study aimed to investigate the association between PDAC prognosis and inflammation‑based markers, such as the neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio, prognostic nutritional index, modified Glasgow prognostic score (mGPS) and controlling nutritional status score. A total of 72 patients with unresectable PDAC who received chemotherapy were included. Inflammation‑based markers were measured prior to treatment. The median progression‑free survival (PFS) and overall survival (OS) were 117 days (range, 10‑781 days) and 244 days (range 43‑781 days), respectively. The cut‑off value of continuous variables that predicted the median OS (244 days) was calcualted. Univariate analysis of PFS showed that disease stage, first‑line chemotherapy regimen, carcinoembryonic antigen (CEA), NLR, platelet‑to‑lymphocyte ratio (PLR), mGPS and controlling nutritional status (CONUT) scores were associated with PFS. Among them, stage, first‑line chemotherapy regimen, CEA, NLR and mGPS were independent prognostic factors for PFS in multivariate analysis. Univariate analysis of OS showed that stage, first‑line chemotherapy regimen, CA19‑9, NLR, PLR, prognostic nutritional index (PNI), mGPS and CONUT score were associated wtih OS. Among them, first‑line chemotherapy and mGPS were independent prognostic factors for OS according to multivariate analysis. Univariate and multivariate analyses revealed that a NLR ≥4.0 and mGPS 2 were independent prognostic factors for PFS. For OS, mGPS 2 was an independent prognostic factor. In conclusion, mGPS was the most useful marker in predicting the prognosis of patients with unresectable PDAC who received chemotherapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zahorec R: Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 102:5–14. 2001.(In English, Slovak). PubMed/NCBI
3	Walsh SR, Cook EJ, Goulder F, Justin TA and Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 91:181–184. 2005. View Article : Google Scholar : PubMed/NCBI
4	An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH and Jiang WQ: Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 15:516–522. 2010. View Article : Google Scholar : PubMed/NCBI
5	Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology. 57:640–645. 2010.PubMed/NCBI
6	Lowe EF, Stein M, Woolley T, Waycaster M, Scroggins B, Acuff R, Smith JT and Lefemine AA: Prognostic nutritional index: Its usefulness as a predictor of clinical course. J Am Coll Nutr. 2:231–240. 1983. View Article : Google Scholar : PubMed/NCBI
7	Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S and Nakao A: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011. View Article : Google Scholar : PubMed/NCBI
8	Geng Y, Qi Q, Sun M, Chen H, Wang P and Chen Z: Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol. 41:1508–1514. 2015. View Article : Google Scholar : PubMed/NCBI
9	Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW and McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 6:450–453. 2006. View Article : Google Scholar : PubMed/NCBI
10	Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et al: Evaluation of modified glasgow prognostic score for pancreatic cancer: A retrospective cohort study. Pancreas. 45:211–217. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, Rodríguez F and Fernández G: CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 20:38–45. 2005.
12	Iseki Y, Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T, Muguruma K, Tanaka H, Toyokawa T, et al: Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS One. 10:e01324882015. View Article : Google Scholar : PubMed/NCBI
13	Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, et al: Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 11:3441–3445. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
15	Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR and Berry DP: Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 35:868–872. 2011. View Article : Google Scholar : PubMed/NCBI
16	Song W, Tian C, Wang K, Zhang RJ and Zou SB: Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis. PLoS One. 12:e01787622017. View Article : Google Scholar : PubMed/NCBI
17	Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, Futagawa Y, Ohashi T and Yanaga K: Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 158:360–365. 2015. View Article : Google Scholar : PubMed/NCBI
18	Morinaga S, Murakawa M, Katayama Y, Yamaoku K, Aoyama T, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M and Morimoto M: Glasgow prognostic score predicts clinical outcomes in patients with pancreatic cancer undergoing adjuvant gemcitabine monotherapy after curative surgery. Anticancer Res. 35:4865–4870. 2015.PubMed/NCBI
19	Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S and Chiba T: Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 3:406–415. 2014. View Article : Google Scholar : PubMed/NCBI
20	Shimoda M, Katoh M, Kita J, Sawada T and Kubota K: The glasgow prognostic score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy. 56:501–506. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, et al: Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore). 95:e35822016. View Article : Google Scholar : PubMed/NCBI
22	Ahmad J, Grimes N, Farid S and Morris-Stiff G: Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: A systematic review. Hepatobiliary Pancreat Dis Int. 13:474–481. 2014. View Article : Google Scholar : PubMed/NCBI
23	Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K and Scott HR: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 92:1834–1836. 2005. View Article : Google Scholar : PubMed/NCBI
24	McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI